24/7 Market News Snapshot 15 May, 2025 – Cabaletta Bio, Inc. Common Stock (NASDAQ:CABA)

May 15, 2025

DENVER, Colo., 15 May, 2025 (www.247marketnews.com) – (NASDAQ:CABA) are discussed in this article.
Cabaletta Bio, Inc. has recently demonstrated significant momentum in the markets while simultaneously advancing its innovative clinical trial efforts. Today, CABA shares have surged impressively, opening at $1.40 and climbing to $1.627, representing a notable increase of 25.15% from the previous closing price of $1.300. This robust trading activity, reflected in a volume of 1.42 million shares, underscores enhanced investor interest and confidence in the company’s future prospects.

On the clinical front, Cabaletta has made strides in its RESET-Myositis™ program, aimed at addressing severe autoimmune diseases such as myositis, which affects approximately 80,000 patients in the U.S. The company has debuted two new subtype-specific cohorts, each focusing on about 15 patients, to evaluate the therapeutic efficacy of rese-cel (resecabtagene autoleucel). Following a constructive dialogue with the U.S. Food and Drug Administration (FDA), Cabaletta received the Regenerative Medicine Advanced Therapy (RMAT) designation for rese-cel, enhancing the pathway towards expedited treatment development.

Dr. David J. Chang, Chief Medical Officer, emphasized the company’s dedication to offering innovative therapies that can reset the immune system, providing renewed hope for individuals with myositis who have limited treatment alternatives. The updated trial design aims to assess therapeutic effectiveness through a validated clinical improvement score, with initial results anticipated within 26 weeks post-infusion.

Looking ahead, Cabaletta will present new clinical data on rese-cel at the upcoming EULAR 2025 Congress, which will also cover systemic lupus erythematosus (SLE) and systemic sclerosis. As Cabaletta positions itself for a Biologics License Application (BLA) submission in 2027, its substantial financial backing and strategic investments in manufacturing processes underscore the commitment to advancing treatment accessibility for patients in dire need of effective therapies.

Related news for (CABA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.